Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of JNJ-3989 plus nucleos(t)ide analog with or without JNJ-56136379 in chronic hepatitis B
2019-004475-39Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2020
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tomligisiran, bersacapavir, entecavir, tenofovir alafenamide, tenofovir disoproxil fumarate and 1 more in Chronic Hepatitis B (CHB) (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Change in proportion of HBsAg-positive hepatocytes. Started May 2020; status: completed.
02
Drugs
tomligisiranbersacapavirentecavirtenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2019-004475-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004475-39.